NCT05024058 - Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

August 9, 2022

Study Completion Date

August 9, 2022

Conditions

Chronic Inducible Urticaria

Interventions

DRUG

Ligelizumab

Ligelizumab treated groups and arms

OTHER

Placebo

Placebo treated groups and arms

Trial Locations (24)

3002

Novartis Investigative Site, East Melbourne

Novartis Investigative Site, Parkville

4026

Novartis Investigative Site, Debrecen

6720

Novartis Investigative Site, Szeged

7632

Novartis Investigative Site, Pécs

10002

Novartis Investigative Site, Taipei

12462

Novartis Investigative Site, Athens

14004

Novartis Investigative Site, Córdoba

29420

Novartis Investigative Site, North Charleston

34093

Novartis Investigative Site, Istanbul

46026

Novartis Investigative Site, Valencia

47713

Novartis Investigative Site, Evansville

79903

Novartis Investigative Site, El Paso

84107

Novartis Investigative Site, Murray

194156

Novartis Investigative Site, Saint Petersburg

194354

Novartis Investigative Site, Saint Petersburg

198260

Novartis Investigative Site, Saint Petersburg

344022

Novartis Investigative Site, Rostov-on-Don

355000

Novartis Investigative Site, Stavropol

426061

Novartis Investigative Site, Izhevsk

060 01

Novartis Investigative Site, Kežmarok

08901

Novartis Investigative Site, Svidník

08003

Novartis Investigative Site, Barcelona

06100

Novartis Investigative Site, Ankara